Active Pharmacovigilance and Healthcare Utilization
This study highlights the potential value of innovative ways of collecting information about adverse drug events directly from patients.
Genomic Testing and Therapies for Breast Cancer in Clinical Practice
Despite almost universal testing for human-epidermal-growth-factor-receptor-2 (HER2), many women with a HER2-positive cancer may not receive trastuzumab. Fewer women received the newer gene-expression-profile (GEP) test.
Willingness to Recommend a Health Plan: Who Is Dissatisfied and What Don't They Like?
Does Patient Cost Sharing Matter? Its Impact on Recommended Versus Controversial Cancer Screening Services
2 Clarke Drive Cranbury, NJ 08512